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ABSTRACT 
Solubility of the drug has a strong influence to achieve higher bioavailability of the drug in systemic circulation. More than 70% NCEs (new chemical 
entities) are hydrophobic, and practically difficult into solid formulation due to their poor water solubility. Mesoporous silicas (MSP) have been 
used for drug delivery system, especially for poorly water-soluble drugs. Encapsulation and interaction of drugs in MSP can enhance the delivery 
and maintain the stability of the drug. However, the characterization of the drug in MSP is necessary to confirm its molecular state. In this review, 
we present an overview of reports related to the characterization of drug encapsulated into MSP. Encapsulation of drugs in MSP can prevent 
recrystallization of drugs due to its inhibition of crystal nucleation. A porous material in MSP can maintain the drug in a physically stable amorphous 
state. The preventing of drug crystallization in MSP can enhance the solubility and the dissolution rate of drug. Therefore, in this work, attempts 
have been made to understand the molecular state of the drug in MSP. The physicochemical characterization of drug by transmission electron 
microscopy (TEM), scanning electron microscope (SEM), differential scanning calorimetry (DSC), fourier-transform infrared spectroscopy (FTIR), 
powder x-ray diffraction (PXRD) and thermogravimetric analysis (TGA) were discussed. The effect of solvent and methods of drug loading and the 
effect of the shape of MSP on release profiles are also presented. Overall, this review provides information about the characterization of drug 
encapsulated into MSP which will be useful in pharmaceutical formulation development. 
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The solubility of the drug has strong influence to achieve higher 
bioavailability of the drug in systemic circulation [1]. Base on the 
Bio-pharmaceutics Classification System (BCS), the drug in BCS Class 
II and Class IV are poor aqueous solubility [2]. More than 70% NCEs 
(new chemical entities) are hydrophobic, and practically difficult 
into solid formulation due to their poor water solubility [1, 3]. 
Developing strategies to modify the solubility of poorly water-
soluble BCS class II and BCS class IV drugs is one of the greatest 
challenges in pharmaceutical research [4].  
Some previous studies have been reported about the modification of 
drug solubility such as solid dispersions and nanoparticle which 
have led to enhance the dissolution of drugs [5]. However, the 
interactions between polymer and drug in solid dispersions is weak 
and cannot sufficiently stabilize the amorphous state of drug [6]. The 
aggregation of drugs nanoparticle can inhibit the dissolution 
enhancement [7].  
In recent years, researchers have developed nanostructured 
materials for drug delivery. Mesoporous silica (MSP) has been used 
as a drug delivery system on the basis of silica-embedding and its 
biocompatibility. In MSP systems, drugs are adsorbed on the surface 
of silica and can affect the release rate of the drug in the precise sites 
of the body [8]. The drug delivery systems controlled by silica can 
improve therapeutic efficacy and reduce toxicity [9]. Mesoporous 
materials are good material for encapsulation of drug due to having 
a stable structure and well-defined surface properties [10]. The 
application of MSP has been widely reported as an oral drug delivery 
vehicles to increase the dissolution properties of the hydrophobic 
drug. Encapsulation and interaction of drugs in MSP can enhance the 
delivery and maintain the stability of the drug [11].  
In this review, we present an overview of reports related to the 
characterization of drug encapsulated into MSP. Encapsulation of 
drug in MSP can prevent recrystallization of drugs due to its 
inhibition of crystal nucleation. A porous material in mesoporous 
silica can maintain the drug in amorphous state. The preventing of 
drug crystallization in MSP can enhance the solubility and the 
dissolution rate of drug [12, 13]. Therefore, in this work, attempts 
have been made to understand the molecular state of the drug in 
MSP.  
Physicochemical characterization of the drug inside 
mesoporous silica 
Differential scanning calorimetry (DSC) analysis 
The thermal behavior study of the drug in MSP usually used DSC. 
The purpose of using DSC measurement is to confirm that the drug 
can be incorporated inside MSP. The melting point data and glass 
transition data of the drug can clarify that mesoporous silica can 
prevent the recrystallization of the drug [14]. The heat of fusion of 
the endothermic peak of the drug will decrease along with the 
concentration of drug in MSP. Even, if all drugs already incorporated 
in MSP, the melting point of the drug did not exist. This indicated 
that the MSP has been successfully prevented the crystallization of 
drug [15]. The absence of a melting point or a glass transition 
related to monomolecular adsorption of drugs on the silica surface 
[14]. Table 1 presents the summary of a few kinds of literature 
reports the thermal behavior of drug in MSP. 
 
 
Fig. 1: The illustration of thermal behavior of (a) drug intact, (b) 
physical mixture of drug-MSP, (c) drug encapsulated into MSP 
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Table 1: The summary of the thermal behavior analysis of drugs in MSP 




Tm of pure 
drug 
Tm of drug in 
mesoporous silica 
Comment on thermal 
behaviour 
References  
Ibuprofen  Nonsteroidal anti-
inflammatory drug 
SBA-15 78 °C - Successfully prevented the 
crystallization of drug 
5,15 







168 °C - Successfully prevented the 












81 °C - Successfully prevented the 
crystallization of drug 
14 
Glibenclamide  hypoglycaemic agent SBA-15 170 °C - Monomolecular adsorption of 






SBA-15 151.2 °C  Monomolecular adsorption of 








FSM-16 115.0 °C - FBP molecules adsorb into 
the mesopores  
20 
 
Several studies mentioned that the endothermic peak of crystalline 
of drug will appear in the mesoporous system due to the high 
concentration of drug loading exceed the pore capacity. 
Nevertheless, the heat of fusion of drug is lower compared with pure 
drug [15]. The illustration of thermal behavior of drug in 
mesoporous silica can be seen in fig. 1.  
Powder x-ray diffraction (PXRD) analysis  
The purpose of PXRD analysis is to investigate the molecular state of 
drug base on the diffraction peak of crystalline of drug. The limited 
size of mesoporous pore size prevent the formation of x-ray 
detectable crystalline of drug. If all drugs have been incorporated in 
MSP, the drug in mesoporous system did not show the diffraction 
peak of crystalline of drug. Hardly any characteristic peaks were 
observed in the drug-loaded samples, suggesting that some drug 
loaded into MSP was in a nanocrystalline state [21]. Table 2 presents 
the summary of a few literature reports the PXRD analysis of drug in 
MSP. 
Similar to DSC measurement, several studies mentioned that 
diffraction peak of drug will appear in the mesoporous system due 
to the high concentration of drug loading exceed the pore capacity. 
Nevertheless, the diffraction peak intensity of drug is lower 
compared with pure drug [15]. The illustration of diffraction peak of 
drug in MSP system can be seen in fig. 2. 
 
Table 2: The summary of PXRD analysis of drugs in MSP 
Drug Mw (g/mol) Carriers  Diffraction peak Comment on the 
result 
References  
Lovastatin 404.5 Mesoporous carbon Almost undetectable Nanocrystalline 21 
Curcumin  368.38 MCM-41 displayed XRD pattern similar with MCM-41  Nano-sized aggregates  22 
Telmisartan 514.6 mesoporous silica 
nanoparticles 
no crystalline of drug Noncrystalline state  23 
Itraconazole  705.64 Neusilin  Halo pattern  Amorphous state 7 
Piroxicam 331.35 MCM-41 No crystalline peak was detected.  Noncrystalline state  24 
 
 
Fig. 2: The illustration of PXRD measurement of (a) drug intact, 
(b) drug encapsulated into MSP with excessive concentration, 
(c) drug encapsulated into MSP 
Fourier transformed infrared spectroscopy (FTIR) analysis  
The purpose of FTIR analysis is to observe the interaction of drug 
with MSP by the presence of functional group [25]. FTIR can provide 
the information about materials for identification of functional 
groups. Therefore, structural changes of drug and the lack of a 
crystal structure can be detected by FT-IR through the changing in 
bonding chemical groups of drug and MSP. The incorporation of 
drug on the mesoporous surface can be also qualitatively confirmed 
by FT-IR spectra [23].  
The interaction of drug and MSP can be occurred physically and 
chemically. If the drug has interaction with MSP, the peak of drug 
will decrease or less sharp compared with pure drug spectrum [24]. 
The decrease of drug spectra in mesoporous system indicating the 
strong molecular interaction between drug and mesoporous, which 
would suggest to form salt. For physical interaction, the spectra of 
drug and MSP will appear, indicating the drug was adsorbed on the 
outer surface of the porous silica particles [26]. No structural change 
in the FTIR spectra also indicates that the drying process of the drug 
was sufficient to remove the solvent that used for incorporating drug 
into mesoporous [18].  
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The example case of FTIR measurement is an evaluation of 
ibuprofen loaded into MSP. The FTIR spectra of ibuprofen exhibited 
a single characteristic peak at 1711 cm−1 and three characteristic 
peaks between 2800 and 3300 cm−1. MSP A exhibited a stronger 
intensity band from 1300 to 900 cm−1. IBU-MSP A exhibited the 
combined individual characteristic peaks of IBU and MSP A, 
indicating that Ibuprofen was physically adsorbed on the surface of 
MSP. In contrast with IBU-MSP B, the characteristic peak of 
Ibuprofen showed at 1711 cm−1 was decreased to 1591 cm−1
 
, 
indicating the strong intermolecular interactions between ibuprofen 
and MSP, which would suggest forming a salt [26].  
Morphology analysis 
The morphology and particle size of MSP were analyzed by SEM and 
TEM. The purpose of this study is to confirm the shape of MSP and 
investigate the nanoparticle structure of silica. However, the ability 
of SEM to verify the porous in detail is limited. Therefore, TEM is 
used to confirm the porous of silica [23]. The technique of Polarized 
light microscopy (PLM) also can be used to confirm the morphology 
of drug and MSP [26]. To investigate the morphology of the loading 
drug in MSP, the different shape can be used to confirm the 
morphology of drug in MSP using SEM, TEM and LPM. 
The morphology of drug incorporated into MSP is not different with 
pure mesoporous. If the loading of drug increase, some new particles 
at surface of mesoporous will be observed [7, 15, 23]. This result 
indicated that the amount of drug exceeds the capacity of MSP. The 
uniform distribution of drug in MSP can be detected by TEM. The 
parallel stacked silica pore wall structure is well preserved can 
prove the uniform distribution of drug in MSP [15]. The PLM also 
shows similar result with the SEM result. If some bright spots were 
found in the images of drug-MSP, indicating that some drug was 
adsorbed on the outer surface of mesoporous. In contrast, if there is 
no significant difference between drug-MSP and pure MSP, 
indicating all drug already loaded in MSP [26].  
Thermogravimetric analysis (TGA) analysis 
The purpose of TGA analysis in the characterization of drug 
encapsulated into MSP is to quantify the amount of drug 
encapsulated into mesoporous silica. The illustration of TGA analysis 
can be seen in fig. 3. 
 
Fig. 3: The illustration of TGA analysis of (a) MSP, (b) MSP 
functionalized with aminopropyl group (c) washed sample, (d) 
unwashed sample 
 
In the fig. 3, in MSP curve revealed two decreases. The first one is from 
room temperature until 100 °C indicated the mass loss and dehydration 
process of water adsorbed on the MSP. The second decrease is from 100 
to 1000 °C indicated gradual condensation of the surface silanol groups, 
described as the process of dihydroxylation. For the line of b, the curve 
decrease indicating the weight loss of functional groups. Some article 
mentioned about the washed sample and unwashed sample. The 
purpose of this treatment is to quantify the drug only inside MSP. The 
result showed that the mass loss of the unwashed sample is higher than 
the washed sample. It is assumed that in the unwashed sample the drug 
not only inside MSP but also in outside of mesoporous silica. Or in the 
unwashed sample, the formation of the drug inside mesoporous silica 
can be achieved until two or three layers, while in the washed sample 
only a single monolayer [27-29]. 
Nitrogen adsorption and desorption 
The specific area of MSP can be estimated by the nitrogen 
adsorption/desorption isotherms of typical type IV according to the 
IUPAC classification. The value of BET specific surface area (SBET), 
the total pore volume (Vt) and the pore diameter (dBJH) of MSP can 
be seen in table 3. 
Table 3: The total pore volume (Vt) and the pore diameter (dBJH) of MSP 
Materials drug SBet (m2 Vt (cm/g) 3 dbjh (nm) /g) References 
B A B A B A 
 MSN telmisartan 585 527 1.51 1.16 12.9 10.4 23 
SBA-15 Itraconazole 461 436 0.82 0.71 8.4 6.9 5 
SBA-15 Ibuprofen  461 335 0.82 0.51 8.4 6.3 5 
MCM-41 Fenofibrate 1028 - 0.73 - 2.7 - 14 
MCM-41 Lidocaine 1553 827 1.75 1.63 2.61 1.75 30 
MSN Indomethacin 1012 852 0.81 0.60 3.8 3.6 27 
SBA-15 ibuprofen 734 307 1.05 0.57 6.0 5.6 15 
B = Before encapsulation, A = After Encapsulation 
 
Drug loaded were characterized using nitrogen adsorption and 
desorption to investigate how the drug altered the porosity of MSP. 
The change of porosity upon loading drugs indicated that some drug 
had little influence on the porosity. The strong reduction of surface 
area, volume and pore diameter revealed some drug already inside 
MSP. The loading procedures, the interaction between drug-MSP and 
the solvent can effect the loading process of drug into MSP and can 
be characterized by nitrogen adsorption and desorption method [5].  
Effect of solvent selection on drug loading  
The solvent can affect the success of loading drug into MSP. The high 
solubility of the drug in the solvent can achieve a high concentration 
of drug-loaded into MSP [31-33]. However, the previous article 
reported that the solvent with the highest API solubility is not 
necessarily the best candidate for maximizing the API loading due to 
the competition between solvent and drug in the adsorption process. 
For the example valsartan with dichloromethane as the solvent can 
be incorporated into MSP 2x higher than methanol even though the 
concentration of valsartan in methanol was higher than in 
dichloromethane. Similarly, aprepitant loaded into MSP using 
chloroform as a solvent achieved more than 3 x higher loading than 
methanol, even though the concentration of aprepitant in methanol 
was 3x higher than chloroform [34].  
To explore about the solvent effect systematically, Soltys, et al. 
conducted the experiment with the same drug (ibuprofen) and the 
same concentration (10 mg/ml) that was dissolved in six different 
solvent to incorporate the drug into MSP. The result of soltys et al. 
experiment can be seen in table 4. 
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Table 4: The loading of ibuprofen into mesoporous silica at 10 mg/ml in different solvents [34] 
Solvents  Ibuprofen loading (wAPI/w Si %) Solvent dielectric constant 
Ethanol 3.5 24.5 
Isopropanol  3.9 18.0 
Methanol  4.3 33.0 
Acetone  4.8 21.0 
Chloroform  6.4 4.8 
Dichloromethane  8.8 9.1 
 
Base on the table 4, the best performance of loading ibuprofen into 
MSP was dichloromethane. Chloroform is slightly lower than 
dichloromethane but has a higher solubility which can compensate 
for the lower efficiency. Ethanol and isopropanol showed poorly 
result with the loading below 4 %. While methanol and acetone are 
slightly better with the loading of 4.3 % and 4.8 % respectively [34]. 
In this result, we can conclude that the solvent with a lower 
dielectric constant generally performed better compared with the 
higher dielectric constant. This result also similar to the work of 
Stam et al. and makilla et al., which showed the poor performance of 
methanol and better performance of chloroform [35, 36].  
Effect of methods on drug loading  
The understanding of the state of drug adsorbed at the surface of 
MSP is very important. This related to the loading procedures of 
drug incorporated into MSP. Mellaerts et al. reported about the 
comparison of loading procedures of the drug (itraconazole) into 
MSP using three different loading methods, viz, solvent evaporation 
method, incipient wetness impregnation, and melting method [5, 
37]. The result of Mallaert et al. work about itraconazole loading can 
be seen in table 5 [5]. 
Base on the table 5, the result showed that using the solvent method 
either solvent evaporation method or incipient wetness 
impregnation revealed a good agreement between drug loadings 
according to TGA and release under sink conditions. When using 
melt method, larger discrepancies were observed. The thermal 
degradation of itraconazole might be occurred from heat treatment. 
The high viscosity of drug after melted can affect the flow of liquid of 
drug into MSP and prevent a homogenous distribution [5]. 
  
Table 5: The result of itroconazole loading into MSP with various methods 
Formula TGA Sink release 
Solvent-10 % 6.09 6.19 
Solvent-30 % 27.88 26.55 
Impregnation-10 % 6.75 5.44 
Impregnation-30 % 29.53 27.32 
Melt-10 % 7.02 5.15 
Melt-30 % 24.7 22.74 
 
Another method that can be used to incorporate the drug into MSP is 
co-spray drying. Shen et al. have been conducted the incorporation 
of drug (ibuprofen) into MSP using co-spray drying and compared 
with ball milling, impregnation and melt method. The result showed 
that base on PXRD, in weight ratio 50:50 (drug: MSP) using the co-
spray drying method did not show any diffraction peak of the 
crystalline form of ibuprofen. Similar to PXRD result, in DSC 
measurement also did not show the endothermic peak of ibuprofen. 
It is assumed that in ratio 50:50 using co-spray drying, ibuprofen has 
successfully incorporated into MSP. 
In contrast with ball milling, impregnation and melt method, the 
result of PXRD measurement of this method showed that in ratio 
50:50 still revealed the crystalline peak of ibuprofen. In DSC 
measurement, the ratio 50:50 using those methods also showed 
strong endothermic peak of ibuprofen. It is assumed that in ratio 
50:50 using ball milling, impregnation and melt method, some 
ibuprofen still in outside the mesoporous silica. The co-spray drying 
is more efficient compared with ball milling, impregnation and melt 
method due to the rapid drying of atomized solvent can prevent the 
formation of ibuprofen crystal [15].  
Effect of shape on physicochemical properties of MSP 
Many scientists have synthesized MSP to improve the bioavailability of 
poorly water-soluble drugs with varying size, surface charge, and 
morphology of MSP [38]. Shen et al. reported that the pore size and 
particle size of MSP can influence the dissolution profile of ibuprofen. 
To investigate the systematic studies about the effect of shape on the 
dissolution test of poorly-water soluble, Zhang et al. conducted the 
synthesis of MSP with different shapes (spherical and rod) and 
investigated the behavior of MSP in their drug delivery properties [39].  
The result showed that the surface area of the rod-shaped MSP rod-
shaped was 1.3 fold higher than the sphere-shaped. Alkyl alcohol was 
important for controlling the morphologies of MSP. Alcohol can decrease 
the critical micelle concentration triggering the formation of rod-shaped 
MSP [39]. Based on PXRD measurement, the absence of diffraction peaks 
indicated that the rod-shaped and the sphere-shaped of MSP were in the 
amorphous state [40]. In the dissolution test, the drug incorporated into 
rod-shaped MSP was faster than the sphere-shaped. Similar to the 
dissolution test, in the in vivo study showed that the rod-shaped 2.2 fold 
higher than the sphere-shaped. This indicated that the different shape of 
MSP can affect the behaviour of drugs incorporated into MSP [41].  
CONCLUSION 
MSP is a promising method to increase the solubility of poorly 
water-soluble drugs. Encapsulation of drugs in MSP can prevent 
recrystallization of drugs due to its inhibition of crystal nucleation. A 
porous material in MSP can maintain the drug in a physically stable 
amorphous state. The preventing drug crystallization in MSP can 
enhance the solubility and the dissolution rate of drug. Investigation 
of drug encapsulated into mesoporous silica is very important to 
understand the molecular state of drug in MSP. The method and the 
solvent can affect the success of loading drug into MSP. The shape of 
MSP also can affect drug delivery properties. 
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